tommaso-lizzul-shutterstock-com
tommaso lizzul / Shutterstock.com
18 February 2016EuropeCatherine Coombes

Muddied waters: the CRISPR IP landscape in Europe

The continuing interference proceedings in the US concerning clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 systems for gene-editing of eukaryotes have received much media attention. Coverage focuses on two groups: one led by Feng Zhang of the Broad Institute of Harvard University and the Massachusetts Institute of Technology, and the other by Jennifer Doudna of the University of California, Berkeley and Emmanuelle Charpentier of the Helmholtz Centre for Infection Research. The commentary focuses on a potential winner-takes-all scenario.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
19 June 2026   The court overturns a decision granting the German-based company provisional measures and ordering a Chinese medtech rival to stop selling its device in four European countries.
Europe
16 June 2026   In the second of a series of interviews with women judges at the pan-European court, Ulrike Voß talks to Sarah Speight about her career, her views on the court so far, and how more women could be encouraged to join the judiciary.
Europe
11 June 2026   The UPC has dealt Siemens a loss against a rival US medtech company, upholding a key breast imaging patent and addressing a range of issues from infringement and validity to recall orders and software-based workarounds.